In vitro and ex vivo models for evaluating vaginal drug delivery systems

Vaginal drug delivery systems are often preferred for treating a variety of diseases and conditions of the female reproductive tract (FRT), as delivery can be more targeted with less systemic side effects. However, there are many anatomical and biological barriers to effective treatment via the vaginal route. Further, biocompatibility with the local tissue and microbial microenvironment is desired. A variety of in vitro and ex vivo models are described herein for evaluating the physicochemical properties and tox-icity profile of vaginal drug delivery systems. Deciding whether to utilize organoids in vitro or fresh human cervicovaginal mucus ex vivo requires careful consideration of the intended use and the formula-tion characteristics. Optimally, in vitro and ex vivo experimentation will inform or predict in vivo perfor-mance, and examples are given that describe utilization of a range of methods from in vitro to in vivo. Lastly, we highlight more advanced model systems for other mucosa as inspiration for the future in model development for the FRT. (c) 2022 Elsevier B.V. All rights reserved.

Automated summary

Vaginal drug delivery systems are preferred for treating female reproductive tract diseases with fewer systemic side effects, but face anatomical and biological barriers. In vitro and ex vivo models are crucial for evaluating these systems. Advanced model systems for other mucosa can inspire future development for the female reproductive tract.